RxDoctor Payments Data

Joseph Laureti, DO

Cardiovascular Disease · Honesdale, PANPI 1205864550

Payments from drug & device makers

$2,832in general payments, 2019–2025

Across 183 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$533
  • Boehringer Ingelheim$355
  • Actelion Pharmaceuticals US, Inc.$301
  • Pfizer$280
  • AstraZeneca$181
  • Amgen$179
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$2,73497%
  • Education$983%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,832 in reported general payments places this provider in the 60th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$154,087
Medicare patients
1,753
Services billed
3,140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban298$339,786
EntrestoSacubitril/Valsartan147$160,475
JardianceEmpagliflozin129$123,320
XareltoRivaroxaban32$48,299
FarxigaDapagliflozin Propanediol15$14,255
Repatha SureclickEvolocumab18$10,473
MultaqDronedarone Hcl12$9,424
BrilintaTicagrelor11$8,680
Metoprolol Succinate389$5,427
Nebivolol Hcl56$3,122
Atorvastatin Calcium273$2,911
Ranolazine ErRanolazine15$2,245
Ezetimibe47$1,742
Rosuvastatin Calcium93$1,490
Losartan Potassium134$1,473

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$280$339,786298 claims
NovartisEntresto$533$160,475147 claims
Boehringer IngelheimJardiance$355$123,320129 claims
Johnson & JohnsonXarelto$158$48,29932 claims
AstraZenecaFarxiga, Brilinta$181$22,93626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Honesdale

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →